ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma
本文未提供摘要，请点击“查看全文”查看完整内容。